Publications | PubMed=571045 Kaighn M.E., Lechner J.F., Narayan K.S., Jones L.W. Prostate carcinoma: tissue culture cell lines. Natl. Cancer Inst. Monogr. 49:17-21(1978) PubMed=447482 Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17:16-23(1979) PubMed=6244232 Williams R.D. Human urologic cancer cell lines. Invest. Urol. 17:359-363(1980) PubMed=3518877; DOI=10.3109/07357908609038260 Fogh J. Human tumor lines for cancer research. Cancer Invest. 4:157-184(1986) PubMed=3335022 Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:589-601(1988) PubMed=1873816 Isaacs W.B., Carter B.S., Ewing C.M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51:4716-4720(1991) PubMed=8104329; DOI=10.1002/pros.2990230206 Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23:123-134(1993) PubMed=8687134 Pandalai P.K., Pilat M.J., Yamazaki K., Naik H., Pienta K.J. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res. 16:815-820(1996) PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::aid-pros9>3.0.CO;2-H Webber M.M., Bello D., Quader S.T.A. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate 30:58-64(1997) PubMed=9823299 Khan J., Simon R.M., Bittner M., Chen Y., Leighton S.B., Pohida T., Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res. 58:5009-5013(1998) PubMed=10702678; DOI=10.1159/000015432 Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N., Isola J., Visakorpi T., Bergerheim U.S.R., Larsson C. Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet. Cell Genet. 87:225-232(1999) PubMed=10700174; DOI=10.1038/73432 Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24:227-235(2000) PubMed=10754530; DOI=10.1002/(SICI)1097-0045(20000501)43:2<144::aid-pros9>3.0.CO;2-H Suzuki Y., Kondo Y., Himeno S., Nemoto K., Akimoto M., Imura N. Role of antioxidant systems in human androgen-independent prostate cancer cells. Prostate 43:144-149(2000) PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::aid-mc6>3.0.CO;2-H Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Mol. Carcinog. 28:236-246(2000) PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::aid-gcc1076>3.0.CO;2-E Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D. IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines. Genes Chromosomes Cancer 30:143-160(2001) PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3 Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D. The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data. Cancer Genet. Cytogenet. 124:112-121(2001) PubMed=11304728; DOI=10.1002/pros.1045 van Bokhoven A., Varella-Garcia M., Korch C., Hessels D., Miller G.J. Widely used prostate carcinoma cell lines share common origins. Prostate 47:36-51(2001) PubMed=11414198; DOI=10.1007/s004320000207 Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J. Cancer Res. Clin. Oncol. 127:375-386(2001) PubMed=12606952; DOI=10.1038/sj.onc.1206247 Clark J., Edwards S., Feber A., Flohr P., John M., Giddings I., Crossland S., Stratton M.R., Wooster R., Campbell C., Cooper C.S. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 22:1247-1252(2003) PubMed=12725112; DOI=10.1385/1-59259-372-0:21 Russell P.J., Kingsley E.A. Human prostate cancer cell lines. Methods Mol. Med. 81:21-39(2003) PubMed=14518029; DOI=10.1002/pros.10290 van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S. Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205-225(2003) CLPUB00698 van Bokhoven A. Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines. Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands PubMed=15486987; DOI=10.1002/pros.20158 Zhao H., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D. Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate 63:187-197(2005) PubMed=15748285; DOI=10.1186/1479-5876-3-11 Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M. HLA class I and II genotype of the NCI-60 cell lines. J. Transl. Med. 3:11.1-11.8(2005) PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433 Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5:2606-2612(2006) PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001 Azari S., Ahmadi N., Tehrani M.J., Shokri F. Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran. Biologicals 35:195-202(2007) PubMed=17440963; DOI=10.1002/pros.20581 Takeda M., Mizokami A., Mamiya K., Li Y.Q., Zhang J., Keller E.T., Namiki M. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 67:955-967(2007) PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921 Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N. DNA fingerprinting of the NCI-60 cell line panel. Mol. Cancer Ther. 8:713-724(2009) PubMed=20164919; DOI=10.1038/nature08768 Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010) DOI=10.4172/2157-7145.S2-005 Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R. STR profiling of human cell lines: challenges and possible solutions to the growing problem. J. Forensic Res. 2 Suppl. 2:5-5(2011) PubMed=21432867; DOI=10.1002/pros.21383 Tai S., Sun Y., Squires J.M., Zhang H., Oh W.-K., Liang C.-Z., Huang J. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 71:1668-1679(2011) PubMed=22068913; DOI=10.1073/pnas.1111840108 Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011) PubMed=22275356; DOI=10.1074/jbc.M111.302547 Lynch T.P., Ferrer C.M., Jackson S.R., Shahriari K.S., Vosseller K., Reginato M.J. Critical role of O-linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J. Biol. Chem. 287:11070-11081(2012) PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017 Kong D., Yamori T. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg. Med. Chem. 20:1947-1951(2012) PubMed=22347499; DOI=10.1371/journal.pone.0031628 Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C. Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location. PLoS ONE 7:E31628-E31628(2012) PubMed=22384151; DOI=10.1371/journal.pone.0032096 Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T. Identification of cancer cell-line origins using fluorescence image-based phenomic screening. PLoS ONE 7:E32096-E32096(2012) PubMed=22460905; DOI=10.1038/nature11003 Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607(2012) PubMed=22628656; DOI=10.1126/science.1218595 Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336:1040-1044(2012) PubMed=23671654; DOI=10.1371/journal.pone.0063056 Lu Y.-H., Soong T.D., Elemento O. A novel approach for characterizing microsatellite instability in cancer cells. PLoS ONE 8:E63056-E63056(2013) PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342 Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 73:4372-4382(2013) PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018 Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 4:609-620(2013) PubMed=24279929; DOI=10.1186/2049-3002-1-20 Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab. 1:20.1-20.13(2013) PubMed=24504141; DOI=10.3892/ijo.2014.2287 Suetens A., Moreels M., Quintens R., Chiriotti S., Tabury K., Michaux A., Gregoire V., Baatout S. Carbon ion irradiation of the human prostate cancer cell line PC3: a whole genome microarray study. Int. J. Oncol. 44:1056-1072(2014) PubMed=24670534; DOI=10.1371/journal.pone.0092047 Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C. High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. PLoS ONE 9:E92047-E92047(2014) PubMed=25960936; DOI=10.4161/21624011.2014.954893 Boegel S., Lower M., Bukur T., Sahin U., Castle J.C. A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. OncoImmunology 3:e954893.1-e954893.12(2014) PubMed=25485619; DOI=10.1038/nbt.3080 Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33:306-312(2015) PubMed=26256267; DOI=10.1074/mcp.M115.047928 Shah P., Wang X., Yang W., Toghi Eshghi S., Sun S., Hoti N., Chen L., Yang S., Pasay J., Rubin A., Zhang H. Integrated proteomic and glycoproteomic analyses of prostate cancer cells reveal glycoprotein alteration in protein abundance and glycosylation. Mol. Cell. Proteomics 14:2753-2763(2015) PubMed=26589293; DOI=10.1186/s13073-015-0240-5 Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med. 7:118.1-118.7(2015) PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008 Masuishi Y., Kimura Y., Arakawa N., Hirano H. Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment. J. Proteomics 139:77-83(2016) PubMed=27141528; DOI=10.1016/j.dib.2016.04.001 Masuishi Y., Kimura Y., Arakawa N., Hirano H. Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines. Data Brief 7:1302-1305(2016) PubMed=27377824; DOI=10.1038/sdata.2016.52 Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J. Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR. Sci. Data 3:160052-160052(2016) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016) PubMed=27807467; DOI=10.1186/s13100-016-0078-4 Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H. A map of mobile DNA insertions in the NCI-60 human cancer cell panel. Mob. DNA 7:20.1-20.11(2016) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017) PubMed=30244336; DOI=10.1007/s00345-018-2501-6 Samli H., Samli M., Vatansever B., Ardicli S., Aztopal N., Dincel D., Sahin A., Balci F. Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines. World J. Urol. 37:1117-1126(2019) PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132 Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S.M., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R. Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines. Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) PubMed=31404090; DOI=10.1371/journal.pone.0220807 Jeon J.M., Kwon O.K., Na A.-Y., Sung E.J., Cho I.J., Kim M., Yea S.S., Chun S.Y., Lee J.H., Ha Y.-S., Kwon T.G., Lee S. Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells. PLoS ONE 14:E0220807-E0220807(2019) PubMed=31978347; DOI=10.1016/j.cell.2019.12.023 Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P. Quantitative proteomics of the Cancer Cell Line Encyclopedia. Cell 180:387-402.e16(2020) PubMed=32968452; DOI=10.3892/ol.2020.12093 Liu J., Huang Y.-J., Zhu D., Dai Y., Liu D., Zhai Y., Liang X.-G., Wu L., Zhao Q.-W. Establishment and characterization of a docetaxel-resistant human prostate cancer cell line. Oncol. Lett. 20:230.1-230.7(2020) PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010 Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell 40:835-849.e8(2022) |
---|